Lin, Hui Yi External Author

Publications

Sort by

Selected publications

  • A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an oral MEK1/2 inhibitor, in relapsed/refractory multiple myelomaClinical Cancer Research2016 Academic Article GET IT
    Times cited: 7